A new trading day began on Monday, with Avidity Biosciences Inc (NASDAQ: RNA) stock price down -6.58% from the previous day of trading, before settling in for the closing price of $31.60. RNA’s price has ranged from $21.56 to $56.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 49.32% over the last five years. Meanwhile, its annual earnings per share averaged -32.24%. With a float of $111.14 million, this company’s outstanding shares have now reached $119.89 million.
The firm has a total of 391 workers. Let’s measure their productivity. In terms of profitability, gross margin is 87.81%, operating margin of -3477.44%, and the pretax margin is -2957.72%.
Avidity Biosciences Inc (RNA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Avidity Biosciences Inc is 7.55%, while institutional ownership is 103.96%. The most recent insider transaction that took place on Mar 20 ’25, was worth 297,491. In this transaction Chief Medical Officer of this company sold 9,578 shares at a rate of $31.06, taking the stock ownership to the 72,850 shares. Before that another transaction happened on Mar 20 ’25, when Company’s President and CEO sold 31,540 for $31.06, making the entire transaction worth $979,563. This insider now owns 305,871 shares in total.
Avidity Biosciences Inc (RNA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -32.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.06% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Here are Avidity Biosciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 15.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 325.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.90, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -4.30 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Analysing the last 5-days average volume posted by the [Avidity Biosciences Inc, RNA], we can find that recorded value of 1.66 million was better than the volume posted last year of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 38.89%. Additionally, its Average True Range was 2.04.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 9.50%, which indicates a significant decrease from 11.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.09% in the past 14 days, which was higher than the 65.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.48, while its 200-day Moving Average is $38.97. Now, the first resistance to watch is $30.31. This is followed by the second major resistance level at $31.11. The third major resistance level sits at $31.97. If the price goes on to break the first support level at $28.66, it is likely to go to the next support level at $27.80. Now, if the price goes above the second support level, the third support stands at $27.00.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
With a market capitalization of 3.55 billion, the company has a total of 120,212K Shares Outstanding. Currently, annual sales are 10,900 K while annual income is -322,300 K. The company’s previous quarter sales were 2,970 K while its latest quarter income was -102,260 K.
